Upstate Active Clinical Trials
Study Title:
AALL1621: A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#TBD) inChildren and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
What is the purpose of the study? (in Layman's terms, please describe the study)
The overall goal of this study is to find out what effect, good and/or bad, the drug inotuzumab ozogamicin has on children and young adults with relapsed or refractoryB-ALL.
Upstate Institutional Review Board (IRB) Number:
1083652Study/Protocol ID:
AALL1621Study Phase:
Phase IIIPatient Age Group:
ChildrenPrincipal Investigator:
Melanie A ComitoWho is eligible?
> or = 1 year and < 22 years of age at time of enrollmentWhat is involved if I participate?
- How long is the study?
about 3 months - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
No - What tests and procedures are involved?
standard of care
Where will the study take place?
cancer centerOther Information:
noneWho can I contact for more information?
Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]